Cardiovascular disease remains a major cause of morbidity and mortality among people with type 2 diabetes. Epidemiological studies estimate that as many as one in three U.S. adults with type 2 diabetes have undetected subclinical cardiovascular disease (1). David A. D’Alessio, Director of Endocrinology and Metabolism at Duke University School of Medicine, emphasized that “heart health deserves attention throughout the course of treatment, not just after a serious cardiovascul